On February 10, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that management will participate at these upcoming virtual investor conferences (Press release, Delcath Systems, FEB 10, 2022, View Source [SID1234608004]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 17, 2022, at 11:00 AM ET
This is a BTIG hosted event and will not be webcast. Please contact your BTIG representative for further information.

2022 SVB Leerink Global Healthcare Conference
February 18, 2022, at 9:20 AM ET
Webcast link: View Source
To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].

On February 10, 2022 Ascendis Pharma A/S (Nasdaq: ASND) reported that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference (Press release, Ascendis Pharma, FEB 10, 2022, View Source [SID1234607972]). Company executives will participate in a virtual fireside chat hosted by SVB Leerink.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details

Event 11th Annual SVB Leerink Global Healthcare Conference
Location Virtual
Date Wednesday, February 16, 2022
Time 3:00-3:30 p.m. Eastern Time
A live webcast of the event will be available on the Investors and News section of the Ascendis Pharma website at View Source A webcast replay will be available on the site shortly after conclusion of the event and will stay available for 30 days.

On February 10, 2022 Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET (Press release, Genocea Biosciences, FEB 10, 2022, View Source [SID1234607988]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available in the "Events and Presentations" tab of the investor relations section of the Genocea website at View Source A replay of the webcast will be archived for 90 days following the presentation.

On February 10, 2022 Lepu Biopharma of Beijing reported that it has begun taking orders for its $115 million Hong Kong IPO (Press release, Lepu Biopharma, FEB 10, 2022, View Source [SID1234608005]). The company has built a portfolio of oncology candidates that include eight products at clinical-stage, three in pre-clinical development and three combination therapies. It considers its PD-1 antibody a backbone of its development portfolio and has filed NDAs in China for two candidates. Because recent China life science IPOs have not held their value in post-IPO trading, the Lepu IPO will measure the appetite of investors for new biopharma offerings in 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 10, 2022 Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, reported that the Company’s leadership will participate in the following virtual conferences (Press release, Orum Therapeutics, FEB 10, 2022, View Source [SID1234607957]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

● SVB Leerink 11th Annual Global Healthcare Conference – February 14th – 18th, company leadership will be available for meetings

● BMO Biopharma Spotlight Series: Protein – Degraders and Other Next Gen Technologies – February 24th at 10:10am ET, Panel Discussion and Q&A, "Next Gen Therapies – Fighting For "De Grader" Good